This list is an analysis based on recent market events. It's not an investment recommendation.
About
ERYTECH Pharma S.A., a clinical-stage biopharmaceutical company, develops red blood cell-based therapeutics for cancer and orphan diseases in France and the United States. Its lead product candidate is eryaspase, which is in Phase 3 clinical development for the treatment of second-line pancreatic cancer, and in Phase 2 stage for the treatment of triple-negative breast cancer and second-line acute lymphoblastic leukemia patients. The company also engages in developing erymethionase, a preclinical product candidate that consists of methionine-"-lyase in red blood cells to target methionine cancers. The company was incorporated in 2004 and is headquartered in Lyon, France.
The current price of ERYP.PA is €0.80 EUR — it has increased by +0.25% in the past 24 hours. Watch Erytech Pharma stock price performance more closely on the chart.
What is Erytech Pharma stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on Euronext Paris exchange Erytech Pharma stocks are traded under the ticker ERYP.PA.
What is Erytech Pharma revenue for the last year?▼
Erytech Pharma revenue for the last year amounts to 0 EUR.
What is Erytech Pharma net income for the last year?▼
ERYP.PA net income for the last year is -79.64M EUR.
How many employees does Erytech Pharma have?▼
As of September 07, 2026, the company has 149 employees.
In which sector is Erytech Pharma located?▼
Erytech Pharma operates in the Health & Wellness sector.
When did Erytech Pharma complete a stock split?▼
Erytech Pharma has not had any recent stock splits.